Kornimate/medical-research-clean huggingface dataset:
high-dose combination chemotherapy followed by peripheral stem cell transplantation in treating patients with lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. purpose: phase ii trial to study the effectiveness of high-dose combination chemotherapy followed by peripheral stem cell transplantation in treating patients with lung cancer.

objectives: i. evaluate the response rate of high dose chemotherapy followed by autologous peripheral blood stem cell transplantation in the treatment of lung cancer. outline: patients undergo stem cell harvesting. patients receive radiation therapy to primary site and metastatic sites, if necessary. patients receive a high dose of paclitaxel by 24 hour continuous infusion, then stem cells are infused 72 hours later. after a 3-4 week recovery period, patients receive ifosfamide and carboplatin by daily continuous infusion on days -7, -6, -5, and -4. etoposide is administered by continuous infusion twice daily on days -7, -6, -5, and -4. stem cells are again infused on day 0. filgrastim (granulocyte colony-stimulating factor; g-csf) begins on day 0. patients may receive radiotherapy following recovery from chemotherapy. patients are followed weekly for the first 6 months, then periodically for at least 2 years. projected accrual: this study will accrue 30 patients in 3 years.

Eligibility criteria:
disease characteristics: histologically or cytologically diagnosed lung cancer including the following: relapsed limited stage small cell lung cancer (sclc) limited stage sclc responding to conventional radiotherapy extensive stage sclc stage iiib and iv non-small cell lung cancer (nsclc) stages ii-iiia nsclc who are unable or unwilling to undergo surgery but are acceptable candidates for high dose chemotherapy cryopreserved peripheral blood stem cells with cd34 count greater than 2000/mm3 no untreated or uncontrolled brain metastases patient characteristics: age: any age performance status: karnofsky 60-100% life expectancy: not specified hematopoietic: not specified hepatic: bilirubin less than 1.5 times normal sgot less than 1.5 times normal renal: creatinine clearance greater than 50 ml/min pulmonary: left ventricular ejection fraction greater than 45% dlco greater than 40% other: not pregnant or lactating no medical or psychiatric illness preventing informed consent or intensive treatment prior concurrent therapy: concurrent chemotherapy allowed if no evidence of disease progression

Keywords: stage ii non-small cell lung cancer limited stage small cell lung cancer extensive stage small cell lung cancer recurrent small cell lung cancer stage iiia non-small cell lung cancer stage iiib non-small cell lung cancer stage iv non-small cell lung cancer
impact of anesthetic environment the sex ratio of the children of female assistants

Conditions: Anesthesia, General; Anesthetics Adverse Reaction

Summary: the aims of this multi center retrospective study was to determine: * whether the sex ratio of the offspring of female assistants in anesthesia-resuscitation differs from that of the population at large * whether the assistants' work environment at the time of their offspring's conception influences the sex of their offspring


Eligibility criteria:
inclusion criteria: * female assistants in anesthesia-resuscitation in the wallonia-brussels federation (belgium) who conceived one or more children in the course of their training between 2009 and 2019 and who delivered before the end of 2019 (cut-off: midnight on 31 december 2019) exclusion criteria: * male assistants in anesthesia-resuscitation * female assistants in anesthesia-resuscitation who trained before 2009 or after 2019. * female assistants in anesthesia-resuscitation who relied on medically assisted reproduction.

Keywords: anesthesia care providers offspring sex ratio inhalation induction of anesthesia
anterior ethmoidal nerve block in prevention of postoperative agitation

Conditions: Postoperative Agitation: Impaired Awareness, Abnormal Cognitive Function, Confusion, and Verbal and Physical Agitation During Recovery From General Anesthesia; Deviated Nasal Septum; Chronic Rhinosinusitis (Diagnosis); Nasal Polyps

Summary: postoperative agitation is an important complication of general anesthesia, moreover, it has been found with high incidence in ear, nose, throat (ent) surgeries. we aim to study whether anterior ethmoidal nerve block will be successful in reducing postoperative agitation in those patients. study population will be randomized into two groups, treatment and control group. anterior ethmoidal nerve block will be done in treatment group and postoperative agitation compared between these two groups. agitation score will be scored with riker sedation-agitation scale (sas). ho: occurrence of post-operative agitation in patients undergoing nasal surgery with nasal pack under general anesthesia is equal in those with ethmoidal nerve block as compared to those without the block. ha: occurrence of post-operative agitation in patients undergoing nasal surgery with nasal pack under general anesthesia is not equal in those with ethmoidal nerve block as compared to those without the block.


Eligibility criteria:
inclusion criteria: * patients undergoing nasal surgery * under general anesthesia * with nasal packs exclusion criteria: * do not consent to the study. * history of allergy to lignocaine or bupivacaine

Keywords: general anesthesia nasal surgery anterior ehtmoidal nerve block bupivacaine postoperative confusion
ebastine versus mebeverine in ibs patients

Conditions: IBS - Irritable Bowel Syndrome; IBS

Summary: multicenter randomized controlled clinical trial comparing ebastine and mebeverine as treatment of irritable bowel syndrome trial rationale 1. to perform a randomized superiority trial comparing the clinical efficacy of ebastine and mebeverine 2. to evaluate the impact of treatment with ebastine compared to mebeverine on quality of life and quality-adjusted life years primary objective to provide further evidence of the superiority of histamine 1 receptor antagonism as novel treatment for patients with non-constipated ibs, as compared to mebeverine, one of the spasmolytics currently used as first line treatment of ibs. secondary objective(s) to provide evidence that the histamine 1 receptor antagonist ebastine is more effective in reducing abdominal pain compared to the commonly used antispasmodic mebeverine


Eligibility criteria:
inclusion criteria: 1. voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures 2. patients fulfilling the rome iv criteria for non-constipated ibs (ibs-c subtypes will be excluded) 3. no organic cause that can explain the presenting symptoms (exclusion of coeliac disease (blood), lactose intolerance (breath test), inflammatory bowel disease and giardiasis (stool) 4. patients with lactose intolerance can be included if no improvement on lactose free diet during 6 weeks 5. age 18-65 exclusion criteria: 1. history of coeliac disease, food allergy, giardiasis, inflammatory bowel disease, infectious gastroenteritis, motility disorder, serious liver kidney cardiac or pulmonary disease, known cardiac rhythm disorders, insuline-dependent diabetes, psychiatric diseases 2. pregnancy, breast feeding 3. medication: the use of antidepressants or antipsychotics, anti-allergic medication or drugs affecting gastrointestinal motility / visceral sensitivity (anti-cholinergics, antispasmodics, 5-ht3 antagonists, 5-ht4 agonists, loperamide, codeine, laxatives, analgesics: only paracetamol is allowed as analgetic, other analgesics are forbidden.), cyp3a4-inducing and inhibiting drugs. potent inhibitors of cyp3a4 include clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, verapamil, goldenseal and grapefruit. inducers of cyp3a4 include phenobarbital, phenytoin, rifampicin, st. john's wort and glucocorticoids. 4. symptoms started following abdominal surgery 5. ibs constipation dominant (ibs-c) 6. hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the smpc of the respective medicinal products

Keywords: ebastine duspatalin ibs irritable bowel syndrome
antiplatelet secondary prevention international randomised trial after intracerebral haemorrhage (aspiring)-pilot phase

Conditions: Intracerebral Hemorrhage

Summary: aspiring is an investigator-led, multicentre, prospective, randomised, open-label, blind outcome (probe), parallel group, clinical trial. the pilot phase will explore the feasibility of conducting a trial of starting antiplatelet monotherapy versus avoiding antiplatelet therapy for reducing all serious vascular events for adults surviving symptomatic stroke due to spontaneous intracerebral haemorrhage (ich). the pilot phase will involve \~120 patients at \~30 hospitals in china, australia and new zealand.

the participant eligibility criteria specifically identify adults with history of symptomatic spontaneous ich. randomisation occurs if a participant and their doctor are uncertain about whether to start or avoid antiplatelet monotherapy at least 24 hours after ich symptom onset. the intervention is a pragmatic policy of starting antiplatelet monotherapy (one antiplatelet drug available in local standard clinical practice, chosen by patient's physician pre-randomisation). the control group adopts a policy of avoiding antiplatelet therapy.

Eligibility criteria:
inclusion criteria: 1. patient age ≥18 years. 2. symptomatic stroke due to spontaneous (non-traumatic) ich. 3. patient is at least 24 hours after ich symptom onset. 4. patient and their doctor are both uncertain about whether to start or avoid antiplatelet monotherapy. 5. consent to randomisation from the patient (or personal / legal / professional representative if the patient does not have mental capacity). exclusion criteria: 1. ich due to head injury, in the opinion of the investigator. 2. ich due to haemorrhagic transformation of an ischaemic stroke, in the opinion of the investigator. 3. patient is already taking antiplatelet therapy, or full dose anticoagulant therapy, after ich. 4. patient is pregnant, breastfeeding, or of childbearing age and not taking contraception. 5. patient and carer unable to understand spoken or written local language.

Keywords: stroke intracerebral hemorrhage antiplatelet therapy aspirin clopidogrel cilostazol
study on infectious mononucleosis in munich

Conditions: Infectious Mononucleosis; Epstein-Barr Virus Infections

Summary: this observational clinical study aims at the identification of novel biomarkers and causative factors of complicated and/or protracted epstein-barr virus-associated infectious mononucleosis (im). clinical, biochemical, and routine virological data were collected from 200 patients with im, novel analytical tools were implemented, and immunological and virological experimental data were generated using blood samples and mouthwashes. patients have been investigated within four weeks after the onset of symptoms as well as one month and six months thereafter.

ebv-associated diseases are a severe and global health problem, and novel tools and targets for a better pathogenetic understanding, diagnosis, treatment, and prevention are clearly needed. here we propose to use several novel experimental approaches to investigate immunological, virological, biochemical, and clinical features in an observational study on munich im patients. this study aims at identifying biomarkers and causative factors of protracted and/or complicated im to facilitate the development of novel approaches to early diagnosis, therapy, and prevention of severe, life-threatening, and chronic ebv-associated diseases, including post-viral syndromes. two hundred patients with im onset within the last four weeks were recruited from munich health care institutions and were re-investigated at one and six months after the onset of symptoms. a novel diagnostic scoring system was developed to indicate the severity, complexity, and protraction of symptoms. investigated clinical parameters, including reported symptoms and physical signs of im, as well as candidate risk factors in the medical history of patients and family members. peripheral blood was analysed by established and novel analytical assays to determine the immunological and virological phenotypes of im, and viral load was determined in mouthwashes.

Eligibility criteria:
inclusion criteria: * im onset within the last four weeks * with at least one of four typical clinical findings (tonsillopharyngitis, fever, lymphadenopathy, fatigue) - virological findings indicating primary ebv infection (ebv-specific antibodies, ebv dna). exclusion criteria: * pregnancy * transfusion * and/or transplantation during the last year * and/or no informed consent.

Keywords: ebv pfeiffer's glandular fever post-viral syndrome
does the thrombin generation test performed during the pharmacokinetic profile of the substitutive factor viii bring benefits to the personalized treatment of pediatric patients and adult hemophilia a patients under prophylaxis ?

Conditions: Hemophilia

Summary: in the context of hemophilia, it is well know that the level of factor viii alone does not reflect the clinical phenotype of the patients in an accurate way. at equal factor viii levels, certain patients will bleed more than others. the thrombin generation test (tgt) is a test that seems to provide a better prediction of the overall hemostatic status of an individual patient. in a previous study, the investigators have established normal reference values of the thrombin generation curve in children aged 6 months to 16 years and adults. the goal was to evaluate the use of this test in different clinical contexts and in severe hemophilia patients in particular. a pilot study showed that the patients having a thrombin generation \<150 had a severe phenotype, whether those who received an appropriate prophylaxy had a thrombin generation superior to 150. moreover, the investigators now have access to a software tool that allows them to individually determine the pharmacokinetic profile of the factor viii injected to each patient. the factor viii concentration is measured at injection and 30 minutes, 1 hour, 2 hours and 24 hours afterwards. the introduction of these concentrations in the software allows to obtain the half-life of factor for a given patient, the maximum peak, and the minimum factor level (though level). the injected dosis might be sufficient (disappearance of substantial diminution of the bleedings) or unsufficient (persisting bleeding) for a given patient. this study aims: * to measure the pharmacokinetic profile of factor viii by two different methods, the time-based method and the chromogenic method * to correlate the results with the tgt results obtained at the same time points and determine which method gives the best correlation * to link the clinical symptomatology (improved symptomatology or not) with the tgt results * to determine which minimal tgt result is linked to a minimal bleeding rate * to adapt the prophylactic dosis of the patient in a personalized way.


Eligibility criteria:
inclusion criteria: * patients with severe or moderate hemophilia, on prophylaxis, and suffering from bleedings. exclusion criteria: * patients with difficult venous access * patients who have had surgery or trauma in the month before, patients with acute disease (infection, inflammation)

Keywords: thrombin generation test factor viii hemophilia
the treatment of bronchopulmonary dysplasia by instillation ps and mononuclaer cells in preterms

Conditions: Neonates Premature; Ventilator Support

Summary: bronchopulmonary dysplasia mainly occurs in premature infants, which is the main cause of premature infant death.if children with bpd can survive, they are also prone to complications of long-term respiratory diseases such as asthma,that affect the quality of life of bpd children. however, there is no effective treatment method for bpd. so,the investigator would like to investigate the effect of intratracheal ps and mononuclaer cells in pretems

this is a phase 1 clinical trial that constitues one time points cohor and three group,each group with 80 participants,which receive intratracheal ps and mononuclaer cells,receive intratracheal ps,receive intratracheal mononuclaer cells. 1. eligibility criteria:preterm(gestational age more than 28weeks and less than 37weeks) 2. exlusion criteria: preterm infants with major congenital malformations,chromosomal anomalies,inborn errors of metabolism and clinical or laboratory evidence of a congenital infection 3. demographic data and baseline characteristics of the study groups were collected: gestational age(weeks) birth weight(g) gender cesarean section delivery antenatal steroids prolonged rupture of membrane multiple pregnancies apgar score at 5 minutes thrombocytopenia before intervention crp befor intervention(mg/l) tnf-αbefore intervention（pg/ml） 4.autologous cord blood mononuclear cells doses is 25million cells/kg 5.the following are monitored at 3、7、14、21 days after birth: mortality, incidence of bronchopulmonary dysplasia 5.long-term follow up:in 1m，3m，6m,1y:neurodevelopment,asthma，anemia and physic growth

Eligibility criteria:
inclusion criteria: twenty-eight weeks to thirty-seven weeks exclusion criteria: pretem infants with major congenital malformations,chromosomal anomalies,inborn errors of metabolism and clinical or laboratory evidence of a congenital infection

Keywords: ps cord blood mononuclaer cells preterm
attention bias modification treatment (abmt) for patients with post traumatic stress disorder (ptsd)

Conditions: Attention Bias Modification Treatment (ABMT)

Summary: patients with post traumatic stress disorder (ptsd) will be randomly assigned to either attention bias modification treatment (abmt) designed to normalize threat-related attention biases or a placebo control condition not designed to change attention patterns. outcome measures will be post traumatic stress disorder (ptsd), depression, and anxiety symptoms as measured by gold standard questionnaires and symptom counts derived from structured clinical interviews. we expect to see significant post traumatic stress disorder symptom reduction in the attention bias modification treatment (abmt) group relative to the placebo control group in which no symptomatic relief is expected.


Eligibility criteria:
inclusion criteria: * combat-related ptsd diagnosis exclusion criteria: * other treatment

Keywords: attention bias modification treatment cognitive bias modification attention training anxiety
inflammatory response and tissue fibrosis/ lymphatico-venous bypass

Conditions: Breast Cancer; Genitourinary Cancer; Malignant Female Reproductive System Neoplasm; Melanoma; Sarcoma

Summary: the goal of this clinical research study is to measure the amount of inflammatory proteins inside the body before and after lymphatico-venular bypass surgery. this will help doctors learn if anti-fibrotic or anti-inflammatory drugs/treatments given with the surgery can improve how well the surgery works.

if you choose to take part in this study, you will have 1 small piece of tissue (about the size of a pencil eraser) collected from the arm with the lymphedema and another small piece of tissue will be collected from the unaffected arm. a total of 4 samples will be collected by excisional biopsy (2 samples before the surgery and 2 more samples again 6 months after the surgery). to collect an excisional biopsy, the area of skin is numbed with anesthetic and a small cut is made to remove all or part of the affected tissue. blood (about 5 teaspoons each time) will also be drawn before the surgery and 1 more blood sample again 6 months after the surgery. if possible, the blood samples will be collected during already scheduled blood draws to avoid additional needle sticks. the tissue and blood samples will be used for testing to evaluate the level of the tissue inflammation and to check for any build-up of excess tissue. length of study: after both tissue and blood samples have been collected, your participation in this study will be over. this is an investigational study. up to 30 patients will take part in this study. all will be enrolled at md anderson.

Eligibility criteria:
inclusion criteria: 1. patients undergoing lymphatico-venular bypass for lymphedema. 2. history of axillary lymph node dissection, sentinel lymph node biopsy or dissection. 3. a minimum of three (3) months post-op from any surgical interventions. 4. a minimum of six (6) months from the last dose of chemotherapy. 5. patients with unilateral lymphedema. exclusion criteria: 1. active systemic infection or allergic reaction. 2. active parasitic infection. 3. history of primary (congenital) lymphedema. 4. metastatic cancer. 5. history of autoimmune disorders including lupus, rheumatoid arthritis, vasculitis, systemic sclerosis. 6. history of other fibroproliferative disorders including cirrhosis, pulmonary fibrosis, kidney fibrosis, systemic sclerosis, scleroderma. 7. current treatment with steroids. 8. concurrent secondary systemic cancer exclusive of cutaneous malignancies. 9. treatment with myelosuppressive or stimulatory drugs within six (6) months of enrollment. 10. history of bone marrow transplantation.

Keywords: breast cancer genitourinary cancer gynecological cancer malignant female reproductive system neoplasm melanoma sarcoma inflammatory response inflammatory proteins tissue fibrosis lymphatico-venous bypass surgery punch biopsy lab collections th2 immune phenotype lymphedema
the functional profile of people suffering from trigger finger

Conditions: Trigger Finger

Summary: the purpose of this study is to characterize the population of people who suffer from trigger finger (tf) in terms of demographic (gender, age, occupation, etc.); motor skills (hand function); the consequences of the disease on a person's daily functioning and impact on quality of life. the study will also attempt to examine the suitability of several common assessment tool for evaluation of hand rehabilitation patients who suffer from tf. information obtained from the study will enable a deeper comprehension of the consequences of tf on the patient and will be the first step in developing a protocol assessment and evidence-based treatment in this population.


Eligibility criteria:
inclusion criteria: * age 20 and above. * men and women. * diagnosed with trigger finger. exclusion criteria: * trauma in upper extremity. * cognitive difficulties that are blocking the ability to answer the questionnaires (dementia, head injury). * pregnant women. * participants who didnt completed all assessments.

Keywords: trigger finger
intensive upper extremity recovery program for chronic stroke (super)

Conditions: Chronic Stroke

Summary: the purpose of this study is to investigate the feasibility of a high-quality, high-dose, high-intensity upper extremity therapy program and to assess the treatment effects of a high-quality, high-dose, high-intensity upper extremity therapy program on functional outcomes, motor impairment, and quality of life


Eligibility criteria:
inclusion criteria: * single qualifying stroke event as confirmed by ct or mri * at least 6 months post stroke * fugl-meyer upper extremity (ue) score of 20-45 * able to follow written instructions * able to tolerate 6 hours of therapy a day exclusion criteria: * prior arm injury impacting available passive or active range of motion or significant arm pain with movement * active drug or alcohol abuse * diagnosed with advanced dementia * pre-stroke baseline mrs\>3 * history of clinically significant ischemic or hemorrhagic stroke resulting in prior arm weakness in the same territory as the index stroke * medical instability assessed by the treating stroke physician to participate to the study.

Keywords: rehabilitation arm recovery high intensity therapy occupational therapy physical therapy